Boston Properties (BXP)
Boston Properties reported a significant insider buy coming from the company’s CEO on Tuesday. CEO Thomas Owen bought 9,002 shares of Boston Properties at an average price of $111.10 per share. This cost the CEO a total of $1,000,122. Since his buy, the price per share has dropped -1.37%.
Owen’s buy came as the price nears a 5-year high.
Boston Properties is a fully integrated, self-administered and self-managed real estate investment trust that develops, redevelops, acquires, manages, operates and owns a diverse portfolio of Class A office space, one hotel, three residential properties and three retail properties. The company is one of the largest owners and developers of Class A office properties in the United States, concentrated in five markets – Boston, New York, Princeton, San Francisco and Washington DC.
The company offers a snapshot which highlights:
|Equity Value||$17.5 billion|
|Total Consolidated Debt||$8.8 billion|
|Total Combined Market Cap||$27.8 billion|
On June 18, Boston Properties declared a regular quarterly cash dividend of $0.65 per share payable on July 31 to shareholders of the record at the close of business June 28, 2013.
The analysis on Boston Properties reports:
· The company has an expanding operating margin
· The price is close to a 5-year high of $1116.07
· The dividend yield is at a 2-year high
· The P/B ratio is close to a 1-year low of 2.99.
The Peter Lynch Valuation shows the Boston Properties appears to be overvalued:
Boston Properties has a market cap of $16.34 billion; its shares were traded at around $107.65 with a P/E ratio of 69.50 and a P/S ratio of 8.50. The company had an annual average earnings growth of 4.1% over the past 10 years.
There are currently seven gurus that hold stake in Boston Properties. Click here to see their holding histories.
Anacor Pharmaceuticals (ANAC)
Senior VP and CFO Geoffrey Parker bought 20,000 shares of Anacor yesterday. The shares traded at an average price of $5.22 per share. This cost the CFO a total of $104,400. Parker now owns a total of 76,954 shares of company stock. Since his buy, the price per share has dropped -1.53%.
This insider buy marks the first for the company since August 2012.
Anacor Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company has discovered seven product candidates that have reached development.
Anacor recently announced the successful completion of pre-NDA with the FDA for Tavaborole, its drug candidate for the topical treatment of onychomycosis.
The analysis on Anacor reports:
· Revenue has been in decline for the past three years.
· The operating margin is expanding.
· The P/B ratio is at a 3-year high.
Anacor Pharmaceuticals has a market cap of $200.1 million; its shares were traded at around $5.14 with a P/S ratio of 17.10.
There are currently no gurus that hold stake in Anacor Pharmaceuticals.
Rentrak Corporation (RENT)
CEO William Livek bought 5,000 shares of Rentrak yesterday at an average price of $20.56 per share. This transaction cost the CEO a total of $102,800. Livek currently holds 135,028 shares of Rentrak. Since his buy the price has dropped 0.73%.
Director William Engel also added 5,000 shares to his stake yesterday. His shares traded for an average price of $20.58 per share. This cost the director a slightly larger $102,900. Engle currently holds 32,256 shares of Rentrak. Since his buy, the price per share has dropped 0.83%.
Rentrak is a provider of worldwide consumer viewership information, measuring actual viewing behavior of movies and TV everywhere. Rentrak provides the stable audience measurement services that movie, television and advertising professionals across the globe have come to rely on to better deliver their business goals and more precisely target advertising across numerous platforms including box office, multi-screen television and home video.
Rentrak reported its fiscal 2013 fourth quarter and full year financial results on June 13 which reported:
· Consolidated revenue up 16% to $28.5 million for the fourth quarter, up from $24.36 million for the same period last year.
· Advanced Media and Information up 25%.
· Net loss totaled $2 million, or $0.17 per share, for the quarter, up from a net loss of $4.6 million, or $0.41 per share for the same period last year.
· Consolidated revenue for fiscal 2013 grew to $99.2 million, up from $91.1 million last year.
Rentrak has a market cap of $233 million. Its shares were traded at around $20.41 with a P/S ratio of 2.50.
GuruFocus reports that Rentrak Corporation’s revenue has been in decline over the past three years.
Jean-Marie Eveillard, Chuck Royce and Jim Simons all hold a stake in Rentrak. Click here to see their holding histories.
To check out all insider buys and sells click here.
Try a free 7-day trial here!
- Chuck Royce Undervalued Stocks
- Chuck Royce Top Growth Companies
- Chuck Royce High Yield stocks, and
- Stocks that Chuck Royce keeps buying
- Jean-Marie Eveillard Undervalued Stocks
- Jean-Marie Eveillard Top Growth Companies
- Jean-Marie Eveillard High Yield stocks, and
- Stocks that Jean-Marie Eveillard keeps buying